Genmab A/S has closed an offering of $1.5 billion of 6.250% senior secured notes due 2032 and $1.0 billion of 7.250% senior unsecured notes due 2033. The company plans to use the proceeds to fund the pending acquisition of Merus N.V. The Notes will be secured by certain assets of Genmab and its subsidiaries. The offering was made to qualified institutional buyers and non-U.S. persons. Genmab cautions investors that forward-looking statements are subject to risks and uncertainties. The company does not undertake any obligation to update forward-looking statements.

Read more at GlobeNewswire: Genmab Announces Closing of Private Offering of Senior